The Role of High-Flow Nasal Cannula Oxygen Therapy in Exercise Testing and Pulmonary Rehabilitation: A Review of the Current Literature.
Claudio CandiaCarmen LombardiClaudia MerolaPasquale AmbrosinoSilvestro Ennio D'AnnaAldo VicarioStefania De MarcoAntonio MolinoMauro ManiscalcoPublished in: Journal of clinical medicine (2023)
High-flow nasal cannula (HFNC) has recently emerged as a crucial therapeutic strategy for hypoxemic patients both in acute and chronic settings. Indeed, HFNC therapy is able to deliver higher fractions of inspired oxygen (FiO 2 ) with a heated and humidified gas flow ranging from 20 up to 60 L per minute, in a more comfortable way for the patient in comparison with Conventional Oxygen Therapy (COT). In fact, the flow keeps the epithelium of the airways adequately moisturized, thus positively affecting the mucus clearance. Finally, the flow is able to wash out the carbon dioxide in the dead space of the airways; this is also enhanced by a modest positive end-expiratory pressure (PEEP) effect. Recent evidence has shown applications of HFNC in exercise training and chronic settings with promising results. In this narrative review, we explored how HFNC might contribute to enhancing outcomes of exercise training and pulmonary rehabilitation among patients dealing with chronic obstructive pulmonary disease, interstitial lung diseases, and lung cancer.
Keyphrases
- respiratory failure
- carbon dioxide
- chronic obstructive pulmonary disease
- pulmonary hypertension
- cystic fibrosis
- ejection fraction
- newly diagnosed
- type diabetes
- liver failure
- prognostic factors
- lung function
- intensive care unit
- adipose tissue
- mesenchymal stem cells
- high intensity
- obstructive sleep apnea
- body composition
- metabolic syndrome
- air pollution
- patient reported outcomes
- insulin resistance